5,287 Shares in AstraZeneca PLC $AZN Bought by Legacy Capital Group California Inc.

Legacy Capital Group California Inc. bought a new stake in AstraZeneca PLC (NASDAQ:AZN) during the third quarter, according to its most recent filing with the SEC. The firm bought 5,287 shares of the company’s stock, valued at approximately $406,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Modern Wealth Management LLC lifted its holdings in shares of AstraZeneca by 6.5% during the third quarter. Modern Wealth Management LLC now owns 3,919 shares of the company’s stock worth $301,000 after buying an additional 239 shares during the last quarter. Guardian Capital LP increased its position in AstraZeneca by 31.0% during the third quarter. Guardian Capital LP now owns 83,074 shares of the company’s stock worth $6,373,000 after acquiring an additional 19,648 shares during the period. Foresight Global Investors Inc. acquired a new position in AstraZeneca during the 3rd quarter valued at $18,657,000. Longfellow Investment Management Co. LLC acquired a new position in AstraZeneca during the 3rd quarter valued at $3,818,000. Finally, Crossmark Global Holdings Inc. boosted its holdings in AstraZeneca by 0.8% in the 3rd quarter. Crossmark Global Holdings Inc. now owns 54,662 shares of the company’s stock valued at $4,194,000 after purchasing an additional 453 shares during the period. Institutional investors and hedge funds own 20.35% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on AZN shares. HSBC restated a “buy” rating and set a $108.00 price objective on shares of AstraZeneca in a report on Wednesday, December 10th. Morgan Stanley restated an “overweight” rating and set a $103.00 price target on shares of AstraZeneca in a research note on Wednesday, December 3rd. Wall Street Zen cut AstraZeneca from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 17th. Barclays reiterated an “overweight” rating on shares of AstraZeneca in a research report on Tuesday, January 6th. Finally, Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of AstraZeneca in a report on Friday, February 6th. Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, AstraZeneca presently has an average rating of “Moderate Buy” and a consensus price target of $95.75.

AstraZeneca Trading Down 1.6%

Shares of AstraZeneca stock opened at $194.44 on Friday. AstraZeneca PLC has a 12-month low of $122.48 and a 12-month high of $212.71. The stock has a market capitalization of $301.56 billion, a P/E ratio of 64.60, a price-to-earnings-growth ratio of 1.59 and a beta of 0.32. The company has a 50-day simple moving average of $146.71 and a 200 day simple moving average of $106.43. The company has a quick ratio of 0.69, a current ratio of 0.88 and a debt-to-equity ratio of 0.54.

AstraZeneca Announces Dividend

The firm also recently declared a dividend, which will be paid on Monday, March 23rd. Investors of record on Friday, February 20th will be issued a $1.595 dividend. This represents a dividend yield of 156.0%. The ex-dividend date of this dividend is Friday, February 20th. AstraZeneca’s payout ratio is currently 66.26%.

AstraZeneca Profile

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.